双相障碍维持期治疗的新选择——钙通道调节剂与微量胺相关受体1激动剂的临床前景

A New Option for Maintenance Therapy of Bipolar Disorder—Clinical Prospects of Calcium Channel Modulators and Trace Amine-Associated Receptor 1 Agonists

摘要

双相障碍（bipolar disorder，BD）作为一种典型的精神障碍，其发病机制的确认、治疗药物的迭代以及治疗方式的更新均是值得关注的对象。BD维持期的治疗应将“防止复发”作为主要治疗目标，现有治疗药物和方案存在效果有限与副作用显著的局限性，需结合BD发病机制，寻找新的治疗靶点。围绕BD发病机制及治疗策略的新进展，重点综述Ca²⁺信号通路及微量胺相关受体1（trace amine-associated receptor 1，TAAR1）在BD发生发展中的作用，以及钙通道调节剂和TAAR1激动剂等新型治疗策略的研究进展，并分析两者潜在的协同治疗价值，旨在为BD新型治疗靶点的开发及精准治疗策略的优化提供参考。

Abstract

Bipolar disorder (BD), as a typical mental disorder, has attracted increasing attention with respect to the elucidation of its pathogenesis, the development of therapeutic agents, and the optimization of treatment strategies. The primary objective of maintenance treatment for BD is the prevention of relapse. However, the currently available therapeutic drugs and treatment regimens are limited by unsatisfactory efficacy and significant adverse effects, highlighting the need to identify novel therapeutic targets based on the pathogenesis of BD. This review summarizes recent advances in the pathogenesis and therapeutic strategies of BD, with a particular focus on the roles of the Ca²⁺ signaling pathway and trace amine-associated receptor 1 (TAAR1) in the occurrence and development of BD, as well as recent progress in novel therapeutic strategies, including calcium channel modulators and TAAR1 agonists. In addition, the potential synergistic therapeutic value of these two approaches is discussed, with the aim of providing a reference for the development of novel therapeutic targets and the optimization of precision therapeutic strategies for BD.

关键词

钙通道调节剂 / 微量胺相关受体1激动剂 / 双相障碍

Key words

calcium channel modulators / trace amine-associated receptor 1 agonists / bipolar disorder

参考文献

[1] Sparacino G, Verdolini N, Vieta E,et al. Existing and emerging pharmacological approaches to the treatment of Mania: a critical overview[J].Transl Psychiatry, 2022, 12(1): 169.

[2] Kaltenboeck A, Winkler D, Kasper S. Bipolar and related disorders in DSM—5 and ICD—10[J].CNS Spectr, 2016, 21(4): 318-323.

[3] 孙亚麒, 王育梅, 吕仝, 等. 双相障碍维持期药物临床疗效的系统评价和网络Meta分析[J].中华精神科杂志, 2020, 53(6): 527-536.

[4] 方贻儒, 汪作为, 陈俊. 双相障碍近10年临床热点与研究进展[J].中华精神科杂志, 2025, 58(2): 87-93.

[5] Oliva V, Fico G, De Prisco M,et al. Bipolar disorders: an update on critical aspects[J].Lancet Reg Health Eur, 2025, 48: 101135.

[6] Machado—Vieira R, Courtes A C, Zarate C A Jr,et al. Non—canonical pathways in the pathophysiology and therapeutics of bipolar disorder[J].Front Neurosci, 2023, 17: 1228455.

[7] Qiu Q, Yang M, Gong D,et al.Potassium and calcium channels in different nerve cells act as therapeutic targets in neurological disorders[J].Neural Regen Res, 2025, 20(5): 1258-1276.

[8] Perucca E, Taglialatela M. Targeting K_v7 potassium channels for epilepsy[J].CNS Drugs, 2025, 39(3): 263-288.

[9] Bhattacharya A, Lord B, Grigoleit J S,et al. Neuropsychopharmacology of JNJ—55308942: evaluation of a clinical candidate targeting P2X7 ion channels in animal models of neuroinflammation and anhedonia[J].Neuropsychopharmacology, 2018, 43(13): 2586-2596.

[10] Harrison P J, Hall N, Mould A,et al. Cellular calcium in bipolar disorder: systematic review and meta—analysis[J].Mol Psychiatry, 2021, 26(8): 4106-4116.

[11] Li Z, Wan L, Dong J,et al. Trace amine—associated receptors as potential targets for the treatment of anxiety and depression[J].Front Pharmacol, 2025, 16: 1598048.

[12] Kane J M. A new treatment paradigm: targeting trace amine—associated receptor 1 (TAAR1) in schizophrenia[J].J Clin Psychopharmacol, 2022, 42(5 Suppl 1): S1-S13.

[13] Li Z, Li D, Chen X. Characterizing the polygenic overlaps of bipolar disorder subtypes with schizophrenia and major depressive disorder[J].J Affect Disord, 2022, 309: 242-251.

[14] Dubovsky S L, Marshall D. Calcium channel antagonists for mood disorders[J].J Clin Psychopharmacol, 2022, 42(2): 188-197.

[15] Kageyama Y, Okura S, Sukigara A,et al. The association among bipolar disorder, mitochondrial dysfunction, and reactive oxygen species[J].Biomolecules, 2025, 15(3): 383.

[16] Catterall W A, Perez—Reyes E, Snutch T P,et al. Voltage—gated calcium channels in GtoPdb v.2021.2[J].IUPHAR, 2021, 2021(2): 1-12.

[17] Weiss F, Caruso V, de Rosa U,et al. The role of NMDA receptors in bipolar disorder: a systematic review[J].Bipolar Disord, 2023, 25(8): 624-636.

[18] Yoon S, Iqbal H, Kim S M,et al. Phytochemicals that act on synaptic plasticity as potential prophylaxis against stress—induced depressive disorder[J].Biomol Ther, 2023, 31(2): 148-160.

[19] Vecera C M, Jones G, Chong A C,et al. Intracellular signaling cascades in bipolar disorder[M]//Biomarkers in Bipolar Disorders. Amsterdam: Elsevier, 2022: 331-347.

[20] Manzar A, Sic A, Banh C,et al. Therapeutic potential of calcium channel blockers in neuropsychiatric, endocrine and pain disorders[J].Cells, 2025, 14(14): 1114.

[21] Nunes E J, Addy N A. L—type calcium channel regulation of dopamine activity in the ventral tegmental area to nucleus accumbens pathway: implications for substance use, mood disorders and co—morbidities[J].Neuropharmacology, 2023, 224: 109336.

[22] Tully P J, Peters R, Pérès K,et al. Effect of SSRI and calcium channel blockers on depression symptoms and cognitive function in elderly persons treated for hypertension: three city cohort study[J].Int Psychogeriatr, 2018, 30(9): 1345-1354.

[23] Tokumitsu H, Sakagami H. Molecular mechanisms underlying Ca²⁺/calmodulin—dependent protein kinase kinase signal transduction[J].Int J Mol Sci, 2022, 23(19): 11025.

[24] Haenen N, Kamperman A M, Prodan A,et al. The efficacy of lamotrigine in bipolar disorder: a systematic review and meta—analysis[J].Bipolar Disord, 2024, 26(5): 431-441.

[25] de Bruyn K, Diekman E F, van der Ley C P,et al. Simultaneous mass spectrometric quantification of trace amines, their precursors and metabolites[J].Chromatogr B Analyt Technol Biomed Life Sci, 2024, 1238: 124098.

[26] Peng L, Zhang J, Feng J,et al. Activation of trace amine—associated receptor 1 ameliorates PTSD—like symptoms[J].Biochem Pharmacol, 2024, 228: 116236.

[27] Biso L, Carli M, Scarselli M,et al. Overview of novel antipsychotic drugs: state of the art, new mechanisms, and clinical aspects of promising compounds[J].Biomedicines, 2025, 13(1): 85.

[28] Rutigliano G, Zucchi R. Molecular variants in human trace amine—associated receptors and their implications in mental and metabolic disorders[J].Cell Mol Neurobiol, 2020, 40(2): 239-255.

[29] Imbriglio T, Alborghetti M, Bruno V,et al. Up—regulation of the trace amine receptor, TAAR—1, in the prefrontal cortex of individuals affected by schizophrenia[J].Schizophr Bull, 2024, 50(2): 374-381.

[30] Shemiakova T S, Efimova E V, Gainetdinov R R. TAARs as novel therapeutic targets for the treatment of depression: a narrative review of the interconnection with monoamines and adult neurogenesis[J]. Biomedicines, 2024, 12(6): 1263.

[31] Halff E F, Rutigliano G, Garcia—Hidalgo A,et al. Trace amine—associated receptor 1 (TAAR1) agonism as a new treatment strategy for schizophrenia and related disorders[J].Trends Neurosci, 2023, 46(1): 60-74.

[32] Xu Z, Guo L, Yu J,et al. Ligand recognition and G—protein coupling of trace amine receptor TAAR1[J].Nature, 2023, 624(7992): 672-681.

[33] Liu J, Wu R, Li J X. TAAR1 as an emerging target for the treatment of psychiatric disorders[J].Pharmacol Ther, 2024, 253: 108580.

[34] Dalvi S, Bhatt L K. Trace amine—associated receptor 1 (TAAR1): an emerging therapeutic target for neurodegenerative, neurodevelopmental, and neurotraumatic disorders[J].Naunyn Schmiedebergs Arch Pharmacol, 2025, 398(5): 5057-5075.

[35] Krasner H, Ong C V, Hewitt P,et al. From stress to synapse: the neuronal atrophy pathway to mood dysregulation[J].Int J Mol Sci, 2025, 26(7): 3219.

[36] Zhang B, Zhao J, Wang Z,et al. DL0410 attenuates oxidative stress and neuroinflammation viaBDNF/TrkB/ERK/CREB and Nrf2/HO—1 activation[J].Int Immunopharmacol, 2020, 86: 106729.

[37] 孙萌, 张晨琛, 李继涛, 等. 痕量胺相关受体1信号转导通路的研究进展[J].生理学报, 2024, 76(1): 89-96.

[38] 王芳. 不同强度跑台运动通过调控BDNF/miR—124/p—CREB信号通路改善CUMS小鼠抑郁样行为[J].河南师范大学学报(自然科学版), 2025, 53(3): 27-34.

[39] Shi X, Swanson T L, Miner N B,et al. Activation of trace amine—associated receptor 1 stimulates an antiapoptotic signal cascade viaextracellular signal—regulated kinase 1/2[J].Mol Pharmacol, 2019, 96(4): 493-504.

[40] Giménez—Palomo A, Vieta E. The potential of TAAR1 agonists in bipolar disorder[J].Eur Neuropsychopharmacol, 2022, 62: 4-6.

[41] Harmeier A, Obermueller S, Meyer C A,et al. Trace amine—associated receptor 1 activation silences GSK3β signaling of TAAR1 and D2R heteromers[J].Eur Neuropsychopharmacol, 2015, 25(11): 2049-2061.

[42] Kuvarzin S R, Sukhanov I, Onokhin K,et al. Unlocking the therapeutic potential of ulotaront as a trace amine—associated receptor 1 agonist for neuropsychiatric disorders[J].Biomedicines, 2023, 11(7): 1977.

[43] Tsukada H, Milanovic S M, Darpo B,et al. A randomized, single—dose, crossover study of the effects of ulotaront on electrocardiogram intervals in subjects with schizophrenia[J].Clin Transl Sci, 2023, 16(6): 1063-1074.

[44] Alnefeesi Y, Murtazina R Z, Gainetdinov R R. Trace amine—associated receptors (TAARs): candidate targets in the treatment of bipolar disorders[J]. Actas Esp Psiquiatr, 2025, 53(5): 1140-1153.

[45] Tsytsarev V, Vaganova A N, Volnova A,et al. Role of glial trace amine associated receptor 1 (TAAR1) and microbiota in schizophrenia[J].Neurochem Res, 2025, 50(5): 273.

[46] Sun M, Zhang Y, Zhang X Q,et al. Dopamine D1 receptor in medial prefrontal cortex mediates the effects of TAAR1 activation on chronic stress—induced cognitive and social deficits[J].Neuropsychopharmacology, 2024, 49(8): 1341-1351.

[47] Guan W. The role of trace amine—associated receptor 1 (TAAR1) in the pathophysiology and treatment of depression[J]. Curr Neuropharmacol, 2026, 24(3): 295-308.

[48] Leo D, Targa G, Espinoza S,et al. Trace amine associate receptor 1 (TAAR1) as a new target for the treatment of cognitive dysfunction in Alzheimer’s disease[J].Int J Mol Sci, 2022, 23(14): 7811.

[49] Dubovsky S L. Applications of calcium channel blockers in psychiatry: pharmacokinetic and pharmacodynamic aspects of treatment of bipolar disorder[J].Expert Opin Drug Metab Toxicol, 2019, 15(1): 35-47.

[50] Yang S M, Ghoshal A, Hubbard J M,et al. TAAR1 agonist ulotaront modulates striatal and hippocampal glutamate function in a state—dependent manner[J].Neuropsychopharmacology, 2024, 49(7): 1091-1103.